Immunogenicity does not constitute a barrier to interchangeability between biosimilars infliximab in chronic inflammatory diseases. “There are still consequences of immunogenicity that are not negligible with increased risk of allergic reactions, even though they were quite low in our cohort,” concluded Dr Jéróme Avouac (Paris Descartes University, France) .
The use of biosimilars has taken off in the past few years and is expected to increase further. The debate on the use of biosimilars and the switching from reference biologic medicines to biosimilars in rheumatology focuses on the clinical outcomes, including enhanced immunogenicity, compromised safety, or diminished efficacy for patients.
Dr Avouac et al. aimed to determine whether the successive switches from innovator infliximab to a first then second biosimilar increased the risk of immunogenicity during a 3-year observation period. This was done as a prospective, single-centre, observati...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Support for Tocilizumab Use in Giant Cell Arteritis Next Article
Integrated 10-year Analysis Confirms Safety Profile Abatacept »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.